WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience
 QUICK SEARCH:   [advanced]


     
-


HOME
  |  
SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, January 12, 2005, 25(2):524-531; doi:10.1523/JNEUROSCI.3800-04.2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (14)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hunt, M. J.
Right arrow Articles by Garcia, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hunt, M. J.
Right arrow Articles by Garcia, R.

 Previous Article  |  Next Article 

Neurobiology of Disease
Ketamine Induces Dopamine-Dependent Depression of Evoked Hippocampal Activity in the Nucleus Accumbens in Freely Moving Rats

Mark J. Hunt, Karima Kessal, and Rene Garcia

Neurobiologie Comportementale, Institut National de la Santé et de la Recherche Médicale, Université de Nice-Sophia Antipolis, 06108 Nice, France

Noncompetitive NMDA receptor antagonists, such as ketamine, induce a transient schizophrenia-like state in healthy individuals and exacerbate psychosis in schizophrenic patients. In rodents, noncompetitive NMDA receptor antagonists induce a behavioral syndrome that represents an experimentally valid model of schizophrenia. Current experimental evidence has implicated the nucleus accumbens in the pathophysiology of schizophrenia and the psychomimetic actions of ketamine. In this study, we have demonstrated that acute systemic administration of ketamine, at a dose known to produce hyperlocomotion and stereotypy, depressed the amplitude of the monosynaptic component of fimbria-evoked field potentials recorded in the nucleus accumbens. A similar effect was observed using the more selective antagonist dizocilpine maleate, indicating the depression was NMDA receptor dependent. Paired-pulse facilitation was enhanced concomitantly with, and in proportion to, ketamine-induced depressed synaptic efficacy, indicative of a presynaptic mechanism of action. Notably, the depression of field potentials recorded in the nucleus accumbens was markedly reduced after a focal 6-hydroxydopamine lesioning procedure in the nucleus accumbens. More specifically, pretreatment with the D2/D4 antagonist haloperidol, but not the D1 antagonist SCH23390 blocked ketamine-induced depression of nucleus accumbens responses. Our findings provide supporting evidence for the contemporary theory of schizophrenia as aberrant excitatory neurotransmission at the level of the nucleus accumbens.

Key words: ketamine; NMDA; nucleus accumbens; evoked field potentials; dopamine; schizophrenia


Received June 1, 2004; revised November 22, 2004; accepted November 22, 2004.




This article has been cited by other articles:


Home page
J. Neurosci.Home page
O. Hikosaka, S. R. Sesack, L. Lecourtier, and P. D. Shepard
Habenula: Crossroad between the Basal Ganglia and the Limbic System
J. Neurosci., November 12, 2008; 28(46): 11825 - 11829.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
D. Centonze, S. Rossi, I. Napoli, V. Mercaldo, C. Lacoux, F. Ferrari, M. T. Ciotti, V. De Chiara, C. Prosperetti, M. Maccarrone, et al.
The Brain Cytoplasmic RNA BC1 Regulates Dopamine D2 Receptor-Mediated Transmission in the Striatum
J. Neurosci., August 15, 2007; 27(33): 8885 - 8892.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
C. H. Large
Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?
J Psychopharmacol, May 1, 2007; 21(3): 283 - 301.
[Abstract] [PDF]



-
-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help

-
Copyright 2009 by Society for Neuroscience ONLINE ISSN: 1529-2401
-